Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 25Neoplasms 12Giant Cell Tumor of Bone 10Prostatic Neoplasms 9Multiple Myeloma 9Neoplasm Metastasis 8Osteoporosis 4Fractures, Bone 4Carcinoma, Non-Small-Cell Lung 4Recurrence 3Kidney Neoplasms 3Carcinoma, Renal Cell 3Bone Neoplasms 3Bone Diseases, Metabolic 3Bone Diseases 3Spinal Cord Compression 2Smoldering Multiple Myeloma 2Parathyroid Neoplasms 2Melanoma 2Lymphoma 2Lung Neoplasms 2Giant Cell Tumors 2Bone Metastases 2Bone Cysts, Aneurysmal 2With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer 1Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer Metastatic 1Paraproteinemias 1

Interventions

Denosumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bone Metastasis From Solid Tumors × Denosumab × Clear all
NCT04494373 2020-08-04

Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of HS-20090 and Xgeva® in Healthy Adults

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 1 Unknown
154 enrolled
Other solid neoplasm

Bone Metastasis From Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡